Viridian Therapeutics, Inc./DE Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Viridian Therapeutics, Inc./DE stock issued during period, value, new issues for the quarter ending 2026-06-30 was $134.97M.
- Viridian Therapeutics, Inc./DE stock issued during period, value, new issues for the quarter ending 2025-03-31 was $4.79M.
- Viridian Therapeutics, Inc./DE stock issued during period, value, new issues for the quarter ending 2024-09-30 was $243.23M.
- Viridian Therapeutics, Inc./DE stock issued during period, value, new issues for the quarter ending 2021-09-30 was $25.40M, a 436.14% increase year-over-year.
- Viridian Therapeutics, Inc./DE stock issued during period, value, new issues for fiscal 2016 was $281.00K, a 97.80% decline from fiscal 2015.
- Viridian Therapeutics, Inc./DE stock issued during period, value, new issues for fiscal 2015 was $12.77M, a 118.43% increase from fiscal 2014.
- Viridian Therapeutics, Inc./DE stock issued during period, value, new issues for fiscal 2014 was $5.84M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $134.97M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $4.79M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $243.23M 10-Q · filed 2024-11-12 | |
| 2021-09-30 | $25.40M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $7.05M 10-Q · filed 2022-11-14 | |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | |
| 2020-09-30 | $4.74M 10-Q · filed 2021-11-05 | |
| 2019-06-30 | $278.00K 10-Q · filed 2020-11-12 | |
| 2019-03-31 | $134.00K 10-Q · filed 2020-05-08 | |
| 2018-03-31 | $37.84M 10-Q · filed 2019-05-09 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | |
| 2017-03-31 | $39.16M 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $281.00K 10-K · filed 2018-03-15 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | $12.77M 10-K · filed 2017-03-24 |
| 2015-09-30 | $4.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | |
| 2015-06-30 | -$37.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | |
| 2015-03-31 | $8.78M 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $5.84M 10-K · filed 2016-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |